ZM 447439, Aurora B kinase inhibitor

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

EGFR (Epidermal Growth Factor Receptor) also known as HER1 or ErbB1 mechanically functions as a cell surface receptor for members of the epidermal growth factor family. It possesses kinase activity and plays role in signal transduction processes that regulate cell proliferation and survival. EGFR forms dimer complexes when activated which initiates a cascade of downstream signaling pathways. It has a molecular mass of around 170 kDa and expresses widely in epithelial tissues including the skin lung and colorectal regions.

Biological function summary

Aurora kinases A and B are essential part of cellular division. Aurora A primarily localizes to the centrosomes and spindle microtubules whereas Aurora B is a component of the chromosomal passenger complex (CPC) aiding in accurate chromosome segregation and cytokinesis. TDP1 (Tyrosyl-DNA Phosphodiesterase 1) functions in the repair of DNA double-strand breaks. These proteins work collectively in maintaining genomic stability ensuring correct cellular replication and repair.

Pathways

EGFR activity links to the MAPK and PI3K/AKT pathways influencing cell cycle progression and survival. Aurora kinases interact with proteins such as PLK1 and Cyclin B in the mitotic pathway coordinating timing and structure of cell division. TDP1 operates in DNA repair pathways alongside proteins like XRCC1 repairing covalent DNA-protein complexes contributing to cellular resistance to certain chemotherapeutic agents.

EGFR overexpression or mutation often associates with various cancers including non-small cell lung cancer and colorectal cancer through persistent activation of downstream signaling pathways. Aurora kinases become overactive in different tumor types contributing to aneuploidy and malignant transformation. TDP1 associates with neurodegenerative disorders like spinocerebellar ataxia and has implications in cancer especially in cancers that utilize topoisomerase I inhibitors for treatment relating closely with DNA repair proteins.